Document is current
Any future updates will be listed below
-
Authors
Schlesinger, Naomi
Edwards, N. Lawrence
Yeo, Anthony E.
Lipsky, Peter E. http://orcid.org/0000-0002-9287-1676
-
Funding
Funding for this research was provided by:
Horizon Pharmaceuticals
- License Information
-
More Information
Article History
Received: 23 March 2020
Accepted: 18 June 2020
First Online: 29 June 2020
Ethics approval and consent to participate
: The design of the two identical RCTs of pegloticase and their OLE that provided the data analyzed in this study (Clinicaltrials.gov identifiers: NCT00325195, NCT01356498) received institutional review board approval for each site, and written informed consent and Health Insurance Portability and Accountability Act assurances were completed for each participant prior to enrollment.
: Not applicable.
: NS reports research grants from Pfizer and Amgen and advisory board/consulting fees from Novartis, Horizon Therapeutics, Selecta Biosciences, Olatec, IFM Therapeutics, and Mallinckrodt Pharmaceuticals.NLE reports consulting fees from Astra Zeneca, Horizon Therapeutics, Ironwood Pharmaceuticals, and SOBI International.AEY reports consulting from Horizon Therapeutics.PEL reports consulting fees from Horizon Therapeutics.
